within Pharmacolibrary.Drugs.ATC.D;

model D04AX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00022833333333333332,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0121,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 1800,            
    Vdp             = 0.0104,
    k12             = 16.2,
    k21             = 16.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D04AX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Doxepin is a tricyclic antidepressant (TCA) primarily used for the treatment of major depressive disorder, anxiety disorders, and insomnia. It is also indicated for pruritus and chronic urticaria. The drug acts mainly by inhibiting the reuptake of norepinephrine and serotonin. Doxepin is approved and is in clinical use, particularly for depression and insomnia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Weber, J, et al., &amp; McCormack, PL (2010). Low-dose doxepin: in the treatment of insomnia. <i>CNS drugs</i> 24(8) 713–720. DOI:<a href=&quot;https://doi.org/10.2165/11200810-000000000-00000&quot;>10.2165/11200810-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20658801/&quot;>https://pubmed.ncbi.nlm.nih.gov/20658801</a></p></li><li><p>Puzantian, T (1998). Mirtazapine, an antidepressant. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 55(1) 44–49. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/55.1.44&quot;>10.1093/ajhp/55.1.44</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9437474/&quot;>https://pubmed.ncbi.nlm.nih.gov/9437474</a></p></li><li><p>Yan, JH, et al., &amp; Midha, KK (2002). Absolute bioavailability and stereoselective pharmacokinetics of doxepin. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 32(7) 615–623. DOI:<a href=&quot;https://doi.org/10.1080/00498250210131879&quot;>10.1080/00498250210131879</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12162857/&quot;>https://pubmed.ncbi.nlm.nih.gov/12162857</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D04AX01;
